Mapping the literature: Role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma

Drugs of Today

Volumn 45, Issue 6, 2009, Pages 403-421

  Le Cesne, Axel ^a   Domont, J ^a   Cioffi, A ^a   Bonvalot, S ^a   Terrier, P ^a   Ray Coquard, I ^b   Alfaro, V ^c   Lebedinsky, C ^c   Santabarbara, P ^c   Blay, J Y ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE LÉON BÉRARD   (France)

^c PharmaMar   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACLACINOMYCIN; BROSTALLICIN; CARBOPLATIN; CHLOROZOTOCIN; CISPLATIN; CYSTEMUSTINE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ELLIPTINIUM; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; INCYCLINIDE; MILTEFOSINE; MITOMYCIN C; MITOXANTRONE; MITOZOLOMIDE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; NIMUSTINE; RALTITREXED; RUBITECAN; SOBLIDOTIN; TEMOZOLOMIDE; TOPOTECAN; TRABECTEDIN; TROFOSFAMIDE; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; REVIEW; SOFT TISSUE SARCOMA;

ANTINEOPLASTIC AGENTS, ALKYLATING; CLINICAL TRIALS, PHASE II AS TOPIC; DIOXOLES; HUMANS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SARCOMA; SOFT TISSUE NEOPLASMS; TETRAHYDROISOQUINOLINES;

EID: 70350068771     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.6.1378934     Document Type: Review

References (138)

1. Clark, M. A., Fisher, C., Judson, I., Thomas, J. M. Soft-tissue sarcomas in adults. N Engl J Med 2005, 353(7): 701-711
2. Casali, P.G., Jost, L., Sleijfer, S., Verweij, J., Blay, J.Y. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008, (19, Suppl. 2): ii89-93.
3. Kane, J.M. 3rd, Kraybill, W.G. Radical operations for soft tissue sarcomas. Surg Oncol Clin N Am 2005, 14(3): 633-48, viii.
4. Cheng, E.Y. Surgical management of sarcomas. Hematol Oncol Clin North Am 2005, 19(3): 451-70, v.
5. Habrand, J.L., Le Pechoux, C. Radiation therapy in the management of adult soft tissue sarcomas. Ann Oncol 2004, (15, Suppl. 4): iv187-91.
6. Spira, A.I., Ettinger, D.S. The use of chemotherapy in soft-tissue sarcomas. Oncologist 2002, 7(4): 348-359
7. O'Byrne, K., Steward, W.P. The role of chemotherapy in the treatment of adult soft tissue sarcomas. Oncology 1999, 56(1): 13-23. (Pubitemid 29043891)
8. Bramwell, V.H., Anderson, D., Charette, M.L. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003, (3): CD003293.
9. Bramwell, V.H., Anderson, D., Charette, M. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: A meta-analysis and clinical practice guideline. Sarcoma 2000, 4(3): 103-112
10. Verweij, J., Mouridsen, H.T., Nielssen, O.S. et al. The present state of the an in chemotherapy for soft tissue sarcomas in adults: The EORTC point of view. Crit Rev Oncol Hematol 1995, 20(3): 193-201.
11. Hartmann, J.T., Patel, S. New drug developments for patients with metastatic soft tissue sarcoma. Curr Oncol Rep 2005, 7(4): 300-306 (Pubitemid 41149676)
12. Verweij, J. Other endpoints in screening studies for soft tissue sarcomas. Oncologist 2008, 13(Suppl. 2): 27-31.
13. Schuetze, S.M., Baker, L.H., Benjamin, R.S., Canetta, R. Selection of response criteria for clinical trials of sarcoma treatment. Oncologist 2008, 13(Suppl. 2): 32-40.
14. Van Glabbeke, M., Verweij, J., Judson, I., Nielsen, O.S. Progression-free rote as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002, 38(4): 543-9. (Pubitemid 34185394)
15. Sekine, I., Tamura, T., Kunitoh, H., Kubota, K., Shinkai, T., Kamiya, Y., Saijo, N. Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer. Ann Oncol 1999, 10(6): 731-733 (Pubitemid 29342381)
16. Pommier, Y., Kohlhagen, G., Bailly, C., Waring, M., Mazumder, A., Kohn, K.W. DNA sequence- and structure-selective alkylotion ofguanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996, 35(41): 13303-13309 (Pubitemid 26349423)
17. Martinez, N., Sanchez-Beato, M., Carnero, A. et al. Transcriptional signature of ecteinascidin 743 (Yondells, trabectedin) in human sarcoma cells explanted from chemonaive patients. Mol Cancer Ther 2005, 4(5): 814-823 (Pubitemid 40767126)
18. Erba, E., Bergamaschi, D., Bassano, L., Damia, G., Ronzoni, S., Faircloth, G.T., D'Incalci, M. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001, 37(1): 97-105. (Pubitemid 32119366)
19. Martinez, E.J., Corey, E.J., Owa, T. Antitumor activity- and gene expression-based profiling of ecteinascidin ET 743 and phthalascidin Pt 650. Chem Biol 2001, 8(12): 1151-1160 (Pubitemid 34029884)
20. Carter, N.J., Keam, S.J. Trabectedin: A review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2007, 67(15): 2257-2276
21. Damia, G., Silvestri, S., Carrassa, L. et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001, 92(4): 583-588 (Pubitemid 32319434)
22. Takebayashi, Y., Pourquier, P., Zimonjic, D.B. et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001, 7(8): 961-966 (Pubitemid 32756435)
23. Furuta, T., Ueda, T., Aune, G., Sarasin, A., Kraemer, K.H., Pommier, Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002, 62(17): 4899-4902 (Pubitemid 34984411)
24. Casado, J.A., Rio, P., Marco, E. et al. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther 2008, 7(5): 1309-1318
25. van Kesteren, C., Twelves, C., Bowman, A. et al. Clinical pharmacology of the novel marine-derived anticancer agent ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs 2002, 13(4): 381-393 (Pubitemid 34454724)
26. Twelves, C., Hoekman, K., Bowman, A. et al. Phase I and pharmacokinetic study of Yondelis (ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer 2003, 39(13): 1842-1851.
27. van Kesteren, C., Cvitkovic, E., Taamma, A. et al. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 2000, 6(12): 4725-4732 (Pubitemid 32110411)
28. Taamma, A., Misset, J. L., Riofrio, M. et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 2001, 19(5): 1256-65. (Pubitemid 32202528)
29. Ryan, D.P., Supko, J.G., Eder, J.P. et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001, 7(2): 231-242
30. Villalona-Calero, M.A., Eckhardt, S.G., Weiss, G. et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res 2002, 8(1): 75-85. (Pubitemid 34101461)
31. Yovine, A., Riofrio, M., Blay, J.Y. et al. Phase II study of ecteinascidin-743 in advanced pretreoted soft tissue sarcoma patients. J Clin Oncol 2004, 22(5): 890-899 (Pubitemid 41103601)
32. Garcia-Carbonero, R., Supko, J.G., Manola, J. et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004, 22(8): 1480-1490 (Pubitemid 41103631)
33. Le Cesne, A., Blay, J.Y., Judson, I. et al. Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 2005, 23(3): 576-584 (Pubitemid 46224235)
34. Miller, A.B., Hoogstraten, B., Staquet, M., Winkler, A. Reporting results of cancer treatment. Cancer 1981, 47(1): 207-214
35. Therasse, P., Eisenhauer, E.A., Verweij, J. RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer 2006, 42(8): 1031-1039
36. Therasse, P., Arbuck, S.G., Eisenhauer, E.A. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3): 205-216
37. Simon, R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10(1): 1-10. (Pubitemid 19099520)
38. Bramwell, V.H., Mouridsen, H.T., Santoro, A. et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 1987, 23(3): 311-321 (Pubitemid 17033680)
39. Nielsen, O.S., Judson, I., van Hoesel, Q. et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2000, 36(1): 61-67 (Pubitemid 30035345)
40. Toma, S., Tucci, A., Villani, G., Carteni, G., Spadini, N., Palumbo, R. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). Anticancer Res 2000, 20(1B): 485-491
41. Kostler, W.J., Brodowicz, T., Attems, Y. et al. Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. Ann Oncol 2001, 12(9): 1281-1288 (Pubitemid 32994758)
42. Nielsen, O.S., Dombernowsky, P., Mouridsen, H. et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 1998, 78(12): 1634-1639 (Pubitemid 28550051)
43. Patel, S.R., Beach, J., Papadopoulos, N., Burgess, M.A., Trent, J., Jenkins, J., Benjamin, R.S. Results of a 2-arm phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer 2003, 97(11): 2848-2852 (Pubitemid 36605154)
44. Verweij, J., van Oosterom, A., Blay, J.Y. et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003, 39(14): 2006-2011
45. Chugh, R., Dunn, R., Zalupski, M.M. et al. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol 2005, 23(15): 3597-3604 (Pubitemid 46243505)
46. Garcia Del Muro, X., Lopez-Pousa, A., Martin, J. et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma. Cancer 2005, 104(8): 1706-1712
47. Hartmann, J.T., Oechsle, K., Huober, J. et al. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs 2006, 24(3): 249-253 (Pubitemid 43723900)
48. Gottdiener, J.S., Mathisen, D.J., Borer, J.S. et al. Doxorubicin cardiotoxlcity: Assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 1981, 94(4, Pt. 1): 430-435 (Pubitemid 11103937)
49. Poveda, A., Lopez-Pousa, A., Martin, J. et al. Phase II clinical trial with pegylated liposomal doxorubicin (CAELYX®/Doxil®) and quality of life evaluation (EORTC QLQ-C30) in adult patients with advanced soft tissue sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). Sarcoma 2005, 9(3-4): 127-132
50. 2 until grade III granulocytopenia as second-line chemotherapy for anthracycline-pretreated advanced soft tissue sarcoma. Tumori 1998, 84: 677-680 (Pubitemid 29086526)
51. Palumbo, R., Palmeri, S., Antimi, M., Gatti, C., Raffo, P., Villani, G., Toma, S. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol 1997, 8(11): 1159-1162 (Pubitemid 27521226)
52. van Oosterom, A.T., Mouridsen, H.T., Nielsen, O.S. et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 2002, 38(18): 2397-2406
53. Le Cesne, A., Antoine, E., Spielmann, M. et al. High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995, 13(7): 1600-1608
54. Antman, K.H., Ryan, L., Elias, A., Sherman, D., Grier, H.E. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989, 7(1): 126-131 (Pubitemid 19089091)
55. Buesa, J.M., Mouridsen, H.T., van Oosterom, A.T. et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. Ann Oncol 1991, 2(4): 307-309
56. Kollmannsberger, C., Brugger, W., Hartmann, J.T., Maurer, F., Bohm, P., Kanz, L., Bokemeyer, C. Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs 1999, 10(5): 453-456 (Pubitemid 30011978)
57. Goldstein, D., Cheuvart, B., Trump, D.L. et al. Phase II trial of carboplatin in soft-tissue sarcoma. Am J Clin Oncol 1990, 13(5): 420-423 (Pubitemid 20344519)
58. Budd, G.T., Metch, B., Balcerzak, S.P., Fletcher, W.S., Baker, L.H., Mortimer, J.E. High-dose cisplatin for metastatic soft tissue sarcoma. Cancer 1990, 65(4): 866-869 (Pubitemid 20063486)
59. Fleming, G. Gemcitabine/docetaxel - welcome to a new standard. Gynecol Oncol 2008, 109(3): 313-315
60. Sleijfer, S., Verweij, J. Trial methodology in soft tissue sarcomas; The 'one plus one is three or zero' phenomenon. Ontologie 2008, 31(1-2): 6-8.
61. Amodio, A., Carpano, S., Manfredi, C. et al. Gemcitabine in advanced stage soft tissue sarcoma: A phase II study. Clin Ter 1999, 150: 17-20.
62. Merimsky, O., Meller, I., Flusser, G. et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: A phase II study. Cancer Chemother Pharmacol 2000, 45(2): 177-181 (Pubitemid 30090250)
63. Svancarova, L., Blay, J.Y., Judson, I.R. et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002, 38(4): 556-559 (Pubitemid 34185396)
64. Spath-Schwalbe, E., Genvresse, I., Koschuth, A., Dietzmann, A., Grunewald, R., Possinger, K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 2000, 11(5): 325-329
65. Ferraresi, V., Ciccarese, M., Cercato, M.C. et al. Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: A mono-institutional phase II study. Cancer Chemother Pharmacol 2008, 63(1): 149-155
66. Verweij, J., Lee, S.M., Ruka, W. et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 2000, 18(10): 2081-2086 (Pubitemid 30324361)
67. Amodio, A., Carpano, S., Paoletti, G. et al. Phase II study of docetaxel in patients with advanced stage soft tissue sarcoma. Clin Ter 1998, 149(2): 121-125
68. Edmonson, J.H., Ebbert, L.P., Nascimento, A.G., Jung, S.H., McGaw, H., Gerstner, J.B. Phase II study of docetaxel in advanced soft tissue sarcomas. Am J Clin Oncol 1996, 19(6): 574-576 (Pubitemid 26384705)
69. Santoro, A., Romanini, A., Rosso, A. et al. Lack of activity of docetaxel in soft tissue sarcomas: Results of a phase II study of the Italian Group on Rare Tumors. Sarcoma 1999, 3(3-4): 177-181 (Pubitemid 30227796)
70. Maki, R.G., Wathen, J.K., Patel, S.R. et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007, 25(19): 2755-2763
71. Hensley, M.L., Blessing, J.A., Degeest, K., Abulafia, O., Rose, P.G., Homesley, H.D. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study. Gynecol Oncol 2008, 109(3): 323-328
72. Ebeling, P., Eisele, L., Schuett, P. et al. Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - A single-center experience. Onkologie 2008;31(1-2): 11-16 (Pubitemid 351252936)
73. Bay, J.O., Ray-Coquard, I., Fayette, J. et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: A retrospective analysis. Int J Cancer 2006, 119(3): 706-11. (Pubitemid 43955727)
74. Duffaud, F., Bui, B., Penel, N. et al. A FNCLCC French Sarcoma Group - GETO multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). TAXOGEM study. J Clin Oncol 2008, 26: Abstract 10511.
75. Bay, J.O., Cabrespine, A., Gilliot, O., Bailly, C., Vincent, C., Mishellany, F., Gimbergues, P. Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment. Bull Cancer 2007, 94: S122-6.
76. Le Cesne, A., Misset, J.L., Demetri, G. et al. Consistent evidence of activity of Ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (STS): Results from a pooled analysis of three pivotal phase II clinical trials (P2CT) and safety profile of a 24h. infusion schedule. Eur J Cancer 2001, Suppl 6: Abstract 114.
77. Demetri, G.D., Chawla, S.P., von Mehren, M. et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: Results of a randomized phase II study of two different schedules. J Clin Oncol 2009, (in press).
78. Keizer, H.J., Crowther, D., Nielsen, O.S. et al. EORTC Group phase II study of oral etoposide for pretreated soft tissue sarcoma. Sarcoma 1997, 1(2): 99-101. (Pubitemid 127500593)
79. Van Glabbeke, M., van Oosterom, A.T., Oosterhuis, J.W. et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 1999, 17(1): 150-157 (Pubitemid 29022388)
80. D'Incalci, M., Erba, E., Damia, G. et al. Unique features of the mode of action of ET-743. Oncologist 2002, 7(3): 210-216 (Pubitemid 34651224)
81. Minuzzo, M., Marchini, S., Broggini, M., Faircloth, G., D'Incalci, M., Mantovani, R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 2000, 97(12): 6780-6784 (Pubitemid 30412791)
82. Bonfanti, M., La Valle, E., Fernandez Sousa Faro, J.M., Faircloth, G., Caretti, G., Mantovani, R., D'Incalci, M. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des 1999, 14(3): 179-186 (Pubitemid 29428023)
83. Jin, S., Gorfajn, B., Faircloth, G., Scotto, K.W. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 2000, 97(12): 6775-6779 (Pubitemid 30412790)
84. van Oosterom, A., Maki, R., Taron, M.A. et al. Correlation between the pattern of DNA repair efficiency and the natural history of patients with advanced sarcoma treated with ET-743 (Yondelis). 29th ESMO Congress Proc 2004, Abst 7450.
85. Schoffski, P., Grosso, F., Taron, M. et al. DNA repair functionality as a molecular signature for sensitivity(S)/resistance (R) in sarcoma patients (pts) treated with trabectedin (ET-743, YondelisR). AACR Meeting Abstracts, Oct 2007: C127.
86. Jimeno, J., Aracil, M., Tercero, J.C. Adding pharmacogenomics to the development of new marine-derived anticancer agents. J Transl Med 2006, 4: 3. (Pubitemid 43103498)
87. Jimeno, J., Schoffski, P., Casali, P. et al. Personalized therapy with trabectedin (YondelisR) in advanced pre-treated sarcomas. Eur J Cancer 2007;5(4): ECCO 14. The European Cancer Conference (Barcelona, 23-27 Sept.), Abst 7505.
88. Rosell, R., Martinez, N., Rodriguez, S. et al. Expression of XPG mRNA and protein as potential biomarker of response to trabectedin in sarcoma patients. AACR Meeting Abstracts, Oct 2007: 297 (Abstract C127).
89. Mitelman, F. Recurrent chromosome aberrations in cancer. Mutat Res 2000, 462/2-3): 247-253 (Pubitemid 30190232)
90. Antonescu, C.R. The role of genetic testing in soft tissue sarcoma. Histopathology 2006, 48: 13-21.
91. Borden, E.C., Baker, L.H., Bell, R.S. et al. Soft tissue sarcomas of adults: State of the translational science. Clin Cancer Res 2003, 9(6): 1941-1956
92. Grosso, F., Forni, C., Frapolli, R. et al. Sensitivity of myxoidround cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcript. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 2007, 25:0000.
93. Simone, M., Tavecchio, M., Erba, E. et al. Pharmacodynamics of Trabectedin on inflammatory pathways. In: American Association for Cancer Research Annual Meeting: Proceedings. Los Angeles, CA; 2007, 2196.
94. Grosso, F., Jones, R.L., Demetri, G.D. et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: A retrospective study. Lancet Oncol 2007, 8(7): 595-602. (Pubitemid 46995623)
95. Dileo, P., Grosso, F., Casanova, M. et al. Trabectedin (T) in metastatic Ewing's family tumors (EFT) patients (pts) progressing after standard chemotherapy. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007, 25: 10040.
96. Grosso, F., Jones, R.L., Blay, J.Y. et al. Trabectedin (T) in soft tissue sarcomas (STS) carriying a chromosomal translocation: An exploratory analysis. In: 13th Annual Connective Tissue Oncology Society Meeting Proceedings. (Seattle, WA) 2007, Abst 900.
97. Le Cesne, A., Gianni, L., Maki, R. et al. Translocation-relateed sarcomas (TRS): A retrospective analysis of activity with trabectedin. ECCO 15-34th ESMO Multidisciplinary Congress (Berlin, 20-24 Sept) 2009, Abst E15-0894.
98. Antman, K.H., Montella, D., Rosenbaum, C., Schwen, M. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 1985, 69(5): 499-504. (Pubitemid 15031398)
99. Patel, S.R., Vadhan-Raj, S., Papadopolous, N., Plager, C., Burgess, M.A., Hays, C., Benjamin, R.S. High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies - dose-response and schedule dependence. J Clin Oncol 1997, 15(6): 2378-2384 (Pubitemid 27251141)
100. Blackledge, G., van Oosterom, A., Mouridsen, H. et al. Doxorubicin in relapsed soft tissue sarcoma: Justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study. Eur J Cancer 1990, 26(2): 139-141 (Pubitemid 20121865)
101. Baker, L.H., Rowinsky, E.K., Mendelson, D. et al. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 2008, 26(34): 5583-5588
102. Pazdur, R., Samson, M.K., Baker, L.H. Aclacinomycin A. Phase II evaluation in advanced soft tissue sarcoma. Am J Clin Oncol 1987, 10(3): 237-239 (Pubitemid 17120764)
103. Leahy, M., Ray-Coquard, I., Verweij, J. et al. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2007, 43(2): 308-315 (Pubitemid 46138040)
104. Mouridsen, H.T., Bramwell, V.H., Lacave, J. et al. Treatment of advanced soft tissue sarcoma with chlorozotocin: A phase II trial of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer Treat Rep 1981, 65(5-6): 509-511 (Pubitemid 11075017)
105. Bramwell, V.H., Brugarolas, A., Mouridsen, H.T. et al. E.O.R.T.C. phase II study of cisplatin in cyvadic-resistant soft tissue sarcoma. Eur J Cancer 1979, 15(12): 1511-1513 (Pubitemid 10214261)
106. Samson, M.K., Baker, L.H., Benjamin, R.S., Lane, M., Plager, C. Cis-dichlorodiammineplatinum(II) in advanced soft tissue and bony sarcomas: A Southwest Oncology Group Study. Cancer Treat Rep 1979, 63(11-12): 2027-2029
107. Thigpen, J.T., Blessing, J.A., Wilbanks, G.D. Cisplatin as second-line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1986, 9(1): 18-20.
108. Chu, O.S., Forouzesh, B., Syed, S. et al. A phase II and pharmacological study of the matrix metalloprotelnase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs 2007, 25(4): 359-367 (Pubitemid 46944843)
109. 2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group. Eur J Cancer 1998, 34(3): 422-423 (Pubitemid 28183846)
110. Somers, R., Rouesse, J., van Oosterom, A., Thomas, D. Phase II study of elliptinium in metastatic soft tissue sarcoma. Eur J Cancer Clin Oncol 1985, 21(5): 591-593 (Pubitemid 15116989)
111. Dombernowsky, P., Buesa, J., Pinedo, H.M. et al. VP-16 in advanced soft tissue sarcoma: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 1987, 23(5): 579-580 (Pubitemid 17057392)
112. Kampe, C.E., Lowenbraun, S., Foster, J., Rosen, G. Oral etoposide in treatment of advanced refractory sarcomas. J Natl Cancer Inst 1992, 84(23): 1836-1837
113. Rose, P.G., Blessing, J.A., Soper, J.T., Barter, J.F. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol 1998, 70(2): 267-271 (Pubitemid 28430942)
114. Verweij, J., Krzemieniecki, K., Kok, T., Poveda, A., van Pottelsberghe, C., van Glabbeke, M., Mouridsen, H. Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult - an EORTC Soft Tissue and Bone Sarcoma Group Study. Eur J Cancer 1993, 29A(2): 208-209
115. van Oosterom, A.T., Santoro, A., Bramwell, V., Davy, M., Mouridsen, H.T., Thomas, D., Sylvester, R. Mitomycin C (MCC) in advanced soft tissue sarcoma: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 1985, 21(4): 459-461 (Pubitemid 15076951)
116. Di Lauro, L., Balice, A., Papaldo, P., Lopez, M. Mitomycin C in the treatment of sarcomas of the soft tissues in the adult in an advanced phase. Clin Ter 1985, 115(2): 83-85
117. Bull, F.E., Von Hoff, D.D., Balcerzak, S.P., Stephens, R.L., Panettiere, F.J. Phase II trial of mitoxantrone in advanced sarcomas: A Southwest Oncology Group Study. Cancer Treat Rep 1985, 69(2): 231-233 (Pubitemid 15170466)
118. Somers, R., Santoro, A., Verweij, J. et al. Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: The EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1992, 28A(4-5): 855-857
119. Verweij, J., Judson, I., Steward, W. et al. Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group Study. Eur J Cancer 1994, 30A(6): 842-843 (Pubitemid 24217344)
120. Wagener, D.J., Somers, R., Santoro, A. et al. Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1991, 27(12): 1604-1605
121. Blay, J.Y., Judson, I., Rodenhuis, S., Hermans, C., Smith, M., van Glabbeke, M., Verweij, J. Phase II study of raltitrexed (Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Anticancer Drugs 1999, 10(10): 873-877 (Pubitemid 30058094)
122. Woll, P.J., Judson, I., Lee, S.M. et al. Temozolomide in adult patients with advanced soft tissue sarcoma: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1999, 35(3): 410-412 (Pubitemid 29151937)
123. Talbot, S.M., Keohan, M.L., Hesdorffer, M., Orrico, R., Bagiella, E., Troxel, A.B., Taub, R.N. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer 2003, 98(9): 1942-1946 (Pubitemid 37310238)
124. Trent, J C., Beach, J., Burgess, M.A., Papadopolous, N., Chen, L.L., Benjamin, R.S., Patel, S.R. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003, 98(12): 2693-2699 (Pubitemid 37509535)
125. Reichardt, P., Oechsle, K., Pink, D. et al. An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs 2003, 21(4): 481-486 (Pubitemid 38124989)
126. Hartmann, J.T., Oechsle, K., Mayer, F., Kanz, L., Bokemeyer, C. Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res 2003, 23(2C): 1899-1901 (Pubitemid 36750864)
127. Patel, S., Keohan, M.L., Saif, M.W. et al. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer 2006, 107(12): 2881-2887
128. Chang, P., Wiernik, P.H. Combination chemotherapy with adriamycin and streptozotocin. I. Clinical results in patients with advanced sarcoma. Clin Pharmacol Ther 1976, 20(5): 605-610
129. Schoenfeld, D.A., Rosenbaum, C., Horton, J., Wolter, J.M., Falkson, C., DeConti, R.C. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 1982, 50(12): 2757-2762 (Pubitemid 13220781)
130. Omura, G.A., Major, F.J., Blessing, J.A., Sedlacek, T.V., Thigpen, J.T., Creasman, W.T., Zaino, R.J. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983, 52(4): 626-632
131. Muss, H.B., Bundy, B., DiSaia, P J., Homesley, H.D., Fowler, W.C. Jr., Creasman, W., Yordan, E. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 1985, 55(8): 1648-1653
132. Borden, E.C., Amato, D.A., Rosenbaum, C. et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987, 5(6): 840-850 (Pubitemid 17119988)
133. Borden, E.C., Amato, D.A., Edmonson, J.H., Ritch, P.S., Shiraki, M. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer 1990, 66(5): 862-867 (Pubitemid 20307916)
134. Antman, K., Crowley, J., Balcerzak, S.P. et al. An intergroup phase III randomized study of doxorubicin and dacarbozine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993, 11(7): 1276-1285 (Pubitemid 23199130)
135. Edmonson, J.H., Ryan, L.M., Blum, R.H., Brooks, J.S., Shiraki, M., Frytak, S., Parkinson, D.R. Randomized comparison of doxorubicin alone versus
136. Santoro, A., Tursz, T., Mouridsen, H. et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995, 13(7): 1537-1545
137. Jelic, S., Kovcin, V., Milanovic, N. et al. Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer 1997, 33(2): 220-225 (Pubitemid 27117718)
138. Le Cesne, A., Judson, I., Crowther, D. et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colonystimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000, 18(14): 2676-2684 (Pubitemid 30463549)